ER+/PR- breast cancers are more common than ER-/PR+; some studies have reported elevated risks associated with current MHT use for this phenotype with point estimates which were intermediate between those for ER+PR+ and ER-PR- [8,28], although heterogeneity in risk by joint ER/PR status was not always established. This evidence concerns the gene PGR and breast carcinoma.